DTIL News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

DT

Mkt Cap

$159.3M

Volume

19.57K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

CPTx appoints Matt Kane as Chief Financial OfficerCPTx announced the appointment of Matt Kane as Chief Financial Officer. Kane brings extensive experience in gene editing and cell therapy, with a track record of raising over $500 million in equity financing and securing strategic partnerships valued at over $4 billion. He previously served as CEO of Celyad Oncology, Tune Therapeutics, and Precision Biosciences. Kane will lead CPTx's financing and partnering activities as the company advances its non-viral DNA-based in vivo CAR T therapies toward clinical studies.GlobeNewswire Inc. · Sep 8, 2026

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastThe global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.GlobeNewswire Inc. · Jul 3, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.GlobeNewswire Inc. · May 26, 2026

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment TrendsThe global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.GlobeNewswire Inc. · Jan 22, 2026

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the DomainThe CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.GlobeNewswire Inc. · Mar 5, 2025

Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82%The global genetic engineering market is expected to grow from USD 1.35 billion in 2023 to USD 8.95 billion by 2033, driven by the increasing demand for biopharmaceutical products made through genetically altered processes. However, the high cost of R&D is a restraint on market growth.GlobeNewswire Inc. · Sep 10, 2024

Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.GlobeNewswire Inc. · Sep 10, 2024

Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.Zacks Investment Research · May 29, 2024

Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:DTIL), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.75, along with a high estimate of $60.00 and a low estimate of $19.00. Observing a 1558.33% increase, the current average has risen from the previous average price target of $3.00. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Precision BioSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $60.00 - Debjit Chattopadhyay Guggenheim Announces Buy $19.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $60.00 - Patrick Trucchio HC Wainwright & Co. Adjusts Buy $60.00 $3.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Precision BioSciences. This information provides a snapshot of how analysts perceive ...Full story available on Benzinga.comBenzinga · May 16, 2024

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue EstimatesKronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

DT

DTILPrecision BioSciences, Inc. Common Stock

DTIL

Pay with—

Available Balance0.00

Your PositionYou don't own any DTIL yet.

Related Tickers

Earnings